Xavier Badia
6PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Sep 28, 2024
Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis.Daniel-Aníbal García-Diego, Xavier Badia, Olga Benítez-Hidalgo
|Aug 23, 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV<sup>+</sup> PTLD).Xavier Badia, Miguel Ángel Calleja, Vicente Escudero-Vilaplana
|Jan 07, 2023
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.José Luis Poveda, Claudia Gómez, Alicia Gil
|May 20, 2022
Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System: the cefiderocol example.Miguel Ángel Calleja, Xavier Badia
|Feb 11, 2022
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.Luis Gros, Alicia Roldán, Almudena Cabero-Martínez
|Aug 30, 2020
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.Xavier Badia, Tania Vico, John Shepherd
Pageof 1
